Literature DB >> 34651053

Adherence to Hepatitis C Therapy in a Shelter-Based Education and Treatment Model Among Persons Experiencing Homelessness.

Jesse Powell1, Margaret Ricco1, Jessica Naugle2, Catherine Magee3, Hayat Hassan1, Carmen Masson4, Grace Braimoh1, Barry Zevin2, Mandana Khalili3,5.   

Abstract

BACKGROUND: Medication adherence is a common reason for treatment deferment in persons experiencing homelessness. We evaluated adherence to hepatitis C virus (HCV) therapy following HCV education in a shelter-based care model.
METHODS: Prospective study conducted at 4 homeless shelters in Minneapolis, Minnesota and San Francisco, California from November 2018 to January 2021. Sixty-three patients underwent HCV education and treatment. Multivariable modeling evaluated factors associated with (1) medication and (2) overall (composite score of medication, laboratory, and clinic visit) adherence.
RESULTS: Median age was 56 years; 73% of participants were male, 43% were Black, 52% had psychiatric illness, and 81% used illicit drugs and 60% used alcohol in the past year. Following education, 52% were extremely confident in their ability to be adherent to HCV therapy. Medication adherence by patient and provider report was 88% and 48%, respectively, and 81% achieved HCV cure. Active alcohol use was associated with less confidence in medication adherence (43% vs 78%, P = .04). Older age was positively (coefficient = 0.3) associated with overall adherence to HCV treatment whereas prior therapy was associated with both medication (odds ratio, 0.08) and overall treatment (coefficient = -0.87) nonadherence.
CONCLUSIONS: Despite imperfect adherence, sustained virologic response rates were still high. Expanding opportunities to treat persons experiencing homelessness in a structured and supportive setting is critical to HCV elimination efforts. Published by Oxford University Press on behalf of Infectious Diseases Society of America 2021.

Entities:  

Keywords:  DAA therapy; health disparity; substance abuse; sustained virologic response; vulnerable populations

Year:  2021        PMID: 34651053      PMCID: PMC8507447          DOI: 10.1093/ofid/ofab488

Source DB:  PubMed          Journal:  Open Forum Infect Dis        ISSN: 2328-8957            Impact factor:   3.835


  20 in total

1.  Hepatitis C treatment outcomes among homeless-experienced individuals at a community health centre in Boston.

Authors:  Marguerite E Beiser; Kamala Smith; Molly Ingemi; Emma Mulligan; Travis P Baggett
Journal:  Int J Drug Policy       Date:  2019-04-06

2.  Toward a more accurate estimate of the prevalence of hepatitis C in the United States.

Authors:  Brian R Edlin; Benjamin J Eckhardt; Marla A Shu; Scott D Holmberg; Tracy Swan
Journal:  Hepatology       Date:  2015-08-25       Impact factor: 17.425

3.  Sofosbuvir-Containing Regimens for Chronic Hepatitis C Are Successful in the Safety-Net Population: A Real-World Experience.

Authors:  Kendall R Beck; Nicole Kim; Mandana Khalili
Journal:  Dig Dis Sci       Date:  2016-10-14       Impact factor: 3.199

4.  Underserved Does Not Mean Undeserved: Unfurling the HCV Care in the Safety Net.

Authors:  Mandana Khalili; Robert J Wong
Journal:  Dig Dis Sci       Date:  2018-12       Impact factor: 3.199

5.  Intensive Pharmacy Care Improves Outcomes of Hepatitis C Treatment in a Vulnerable Patient Population at a Safety-Net Hospital.

Authors:  Ashley N Tran; Rishabh Sachdev; Zachary P Fricker; Michael Leber; Toni Zahorian; Bhavesh Shah; David P Nunes; Michelle T Long
Journal:  Dig Dis Sci       Date:  2018-08-04       Impact factor: 3.199

6.  Glecaprevir/pibrentasvir for 8 weeks in treatment-naïve patients with chronic HCV genotypes 1-6 and compensated cirrhosis: The EXPEDITION-8 trial.

Authors:  Robert S Brown; Maria Buti; Lino Rodrigues; Vladimir Chulanov; Wan-Long Chuang; Humberto Aguilar; Gábor Horváth; Elimelech Zuckerman; Barbara Rosado Carrion; Federico Rodriguez-Perez; Petr Urbánek; Armand Abergel; Eric Cohen; Sandra S Lovell; Gretja Schnell; Chih-Wei Lin; Jiuhong Zha; Stanley Wang; Roger Trinh; Federico J Mensa; Margaret Burroughs; Franco Felizarta
Journal:  J Hepatol       Date:  2019-11-02       Impact factor: 25.083

7.  Patient-reported experiences with direct acting antiviral therapy in an integrated model of hepatitis C care in homeless shelters.

Authors:  Stephanie Kim; Jesse Powell; Jessica Naugle; Margaret Ricco; Catherine Magee; Carmen Masson; Barry Zevin; Dylan Bush; Mandana Khalili
Journal:  J Viral Hepat       Date:  2021-06-08       Impact factor: 3.517

8.  HCV compliance and treatment success rates are higher with DAAs in structured HCV clinics compared to general hepatology clinics.

Authors:  Navdeep Chehl; Anurag Maheshwari; Hwan Yoo; Colleen Cook; Talan Zhang; Sara Brown; Paul J Thuluvath
Journal:  Medicine (Baltimore)       Date:  2019-07       Impact factor: 1.817

9.  Clients' perceptions of barriers and facilitators to implementing hepatitis C virus care in homeless shelters.

Authors:  Carmen L Masson; J Konadu Fokuo; August Anderson; Jesse Powell; Barry Zevin; Dylan Bush; Mandana Khalili
Journal:  BMC Infect Dis       Date:  2020-05-29       Impact factor: 3.090

10.  Race affects SVR12 in a large and ethnically diverse hepatitis C-infected patient population following treatment with direct-acting antivirals: Analysis of a single-center Department of Veterans Affairs cohort.

Authors:  Jihane N Benhammou; Tien S Dong; Folasade P May; Jenna Kawamoto; Ram Dixit; Samuel Jackson; Vivek Dixit; Debika Bhattacharya; Steven B Han; Joseph R Pisegna
Journal:  Pharmacol Res Perspect       Date:  2018-02-22
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.